Results 51 to 60 of about 162,270 (298)

Variant constraint by mRNA vaccines [PDF]

Nature Reviews Immunology, 2021
The currently licensed mRNA vaccines for SARS-CoV-2 can elicit cross-neutralizing antibodies against B.1.351 variants of the virus, but are less potent against these variants.
openaire   +2 more sources

Recent advances in malaria genomics and epigenomics [PDF]

, 2016
Malaria continues to impose a significant disease burden on low- and middle-income countries in the tropics. However, revolutionary progress over the last 3 years in nucleic acid sequencing, reverse genetics, and post-genome analyses has generated step ...
Kirchner, Sebastian, Power, B. Joanne, Waters, Andrew P.   +2 more
core   +1 more source

A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA.

PLoS ONE, 2023
BackgroundCancer patients have an increased risk of a severe COVID-19 infection with higher mortality rate. This study aimed to analyze the levels of anti-SARS-CoV-2 S-RBD IgG and NAB among cancer patients who were vaccinated with COVID-19 vaccines ...
Andhika Rachman, Anggraini Iriani, Lugyanti Sukrisman, Wulyo Rajabto, Nadia Ayu Mulansari, Anna Mira Lubis, Rahmat Cahyanur, Findy Prasetyawati, Dimas Priantono, Bayu Bijaksana Rumondor, Rachelle Betsy, Samuel Juanputra   +11 more
doaj   +2 more sources

Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin [PDF]

, 2019
In this work, we studied the expression kinetics and innate immune response of a self-amplifying mRNA (sa-RNA) after electroporation and lipid-nanoparticle (LNP)-mediated delivery in the skin of mice. Intradermal electroporation of the sa-RNA resulted in
De Temmerman, Joyca, Gitsels, Arlieke, Huysmans, Hanne, Mc Cafferty, Séan, Mui, Barbara L, Sanders, Niek, Tam, Ying K, Vanrompay, Daisy, Zhong, Zifu   +8 more
core   +2 more sources

Global landscape of mRNA vaccine clinical trials: a systematic analysis of ClinicalTrials.gov data

Frontiers in Public Health
mRNA vaccines, as a novel vaccine platform, have rapidly become a global research hotspot driven by the COVID-19 pandemic. This study employs a systematic analysis method based on clinical trial registries to conduct a descriptive statistical analysis of
Sijia Liu, Tiange Zhou, Mengmeng Wang, Wanwan Xiang, Jiancai Wu   +4 more
doaj   +1 more source

mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic

Frontiers in Immunology, 2023
The advent of mRNA vaccines represents a significant advance in the field of vaccinology. While several vaccine approaches (mRNA, DNA, recombinant protein, and viral-vectored vaccines) had been investigated at the start of the COVID-19 pandemic, mRNA ...
Ziyang Xu, David E. Fisher
doaj   +1 more source

By dawn or dusk—how circadian timing rewrites bacterial infection outcomes

FEBS Letters, EarlyView.
The circadian clock shapes immune function, yet its influence on infection outcomes is only beginning to be understood. This review highlights how circadian timing alters host responses to the bacterial pathogens Salmonella enterica, Listeria monocytogenes, and Streptococcus pneumoniae revealing that the effectiveness of immune defense depends not only
Devons Mo, Catherine S. Palmer, Jacqueline M. Kimmey   +2 more
wiley   +1 more source

Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development

Pathogens, 2023
The present use of mRNA vaccines against COVID-19 has shown for the first time the potential of mRNA vaccines for infectious diseases. Here we will summarize the current knowledge about improved mRNA vaccines, i.e., the self-amplifying mRNA (saRNA ...
Christin Schmidt, Barbara S. Schnierle
doaj   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy

Pharmaceutics
Extensive research into mRNA vaccines for cancer therapy in preclinical and clinical trials has prepared the ground for the quick development of immune-specific mRNA vaccines during the COVID-19 pandemic.
Theodora Katopodi, Savvas Petanidis, Eirini Grigoriadou, Doxakis Anestakis, Charalampos Charalampidis, Ioanna Chatziprodromidou, George Floros, Panagiotis Eskitzis, Paul Zarogoulidis, Charilaos Koulouris, Christina Sevva, Konstantinos Papadopoulos, Panagiota Roulia, Stylianos Mantalovas, Marios Dagher, Alexandros Vasileios Karakousis, Nikolaos Varsamis, Konstantinos Vlassopoulos, Vasiliki Theodorou, Chrysi Maria Mystakidou, Nikolaos Iason Katsios, Konstantinos Farmakis, Christoforos Kosmidis   +22 more
doaj   +1 more source